Since prostate cancer is the most frequently diagnosed malignancy among males, the treatment of this disease becomes more and more important. A number of well-established forms of treatment are available in conventional medicine. These treatments are effective, but patients often suffer from considerable side effects (particularly concerning their sexuality), leading to an increased interest in complementary treatments.Misteltoe therapy is a frequently applied complementary treatment in oncological practice, however, the state of knowledge regarding misteltoe therapy in prostate cancer is so far limited to very few publications.Three patients with prostate cancer refused conventional therapies, because they were worried to risk their quality of life (their sexuality in particular).The first case, a fifty-two year old man with prostate cancer classified T1bNoMo with Gleason 6 (3+3). Diagnosed: 13/06/2006 after transurethral resection of the prostate for benign prostate enlargement, PSAlevel: 1,22ng/ml before the operation. He refused radical prostatectomy and never followed conventional cancer therapy. Start with Iscucin ® Populi therapy: 24/11/2006.The second case, a fifty year old man with prostate cancer classified T1cNoMo with Gleason5(2+3), PSA level: 5,2ng/ml. Diagnosed: 14/02/2006. He refused radical prostatectomy and never followed conventional cancer therapy. Start with Iscucin ® Populi therapy: 12/03/2006.The third case, a sixty-one year old man with prostate cancer classifed T3aNoMo with Gleason 7 (3+4), PSA level: 13,6ng/ml. Diagnosed: 22/02/2002. Initial treatment with radiotherapy and hormone therapy (Enantone ® ). This patient refused the continuation of the hormone therapy after 18 months of treatment. After a relapse (03/04/2006): Start with Iscucin ® Populi therapy: 20/06/2006.Patients were followed regularly with clinical examinations, PSA level and MRI investigations.The three patients showed an evidence of improvement of quality of life and no side effects were observed, in particular concerning their sexual life. Two cases showed a complete remission respectively after two and a half years and three years, and one case showed a partial remission after three years.The role of Iscucin ® Populi (WALA) therapy in prostate cancer should be evaluated in future clinical studies.